JP2007503841A - 薬剤作用を決定するための細胞ベースのアッセイ法 - Google Patents

薬剤作用を決定するための細胞ベースのアッセイ法 Download PDF

Info

Publication number
JP2007503841A
JP2007503841A JP2006526218A JP2006526218A JP2007503841A JP 2007503841 A JP2007503841 A JP 2007503841A JP 2006526218 A JP2006526218 A JP 2006526218A JP 2006526218 A JP2006526218 A JP 2006526218A JP 2007503841 A JP2007503841 A JP 2007503841A
Authority
JP
Japan
Prior art keywords
cells
cell
biomap
drug
cell culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007503841A5 (enExample
Inventor
エレン エル． ベルグ
ジェニファー メルローズ
エリック ジェイ． クンケル
Original Assignee
バイオシーク インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシーク インコーポレイティッド filed Critical バイオシーク インコーポレイティッド
Publication of JP2007503841A publication Critical patent/JP2007503841A/ja
Publication of JP2007503841A5 publication Critical patent/JP2007503841A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Toxicology (AREA)
  • Software Systems (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
JP2006526218A 2003-09-03 2004-09-02 薬剤作用を決定するための細胞ベースのアッセイ法 Pending JP2007503841A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50018003P 2003-09-03 2003-09-03
PCT/US2004/028970 WO2005023987A2 (en) 2003-09-03 2004-09-02 Cell-based assays for determining drug action

Publications (2)

Publication Number Publication Date
JP2007503841A true JP2007503841A (ja) 2007-03-01
JP2007503841A5 JP2007503841A5 (enExample) 2007-12-06

Family

ID=34272923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526218A Pending JP2007503841A (ja) 2003-09-03 2004-09-02 薬剤作用を決定するための細胞ベースのアッセイ法

Country Status (6)

Country Link
US (1) US20070072246A1 (enExample)
EP (1) EP1668361A4 (enExample)
JP (1) JP2007503841A (enExample)
AU (1) AU2004271183A1 (enExample)
CA (1) CA2576406A1 (enExample)
WO (1) WO2005023987A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094992A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for analysis of biological dataset profiles
EP1719051A4 (en) * 2004-02-27 2009-06-17 Bioseek Inc BIOLOGICAL RECORDING OF ASTHMA AND ATOPY
US20060141508A1 (en) * 2004-11-30 2006-06-29 Michelle Palmer Cellular signaling pathway based assays, reagents and kits
US9734282B2 (en) 2005-03-28 2017-08-15 Discoverx Corporation Biological dataset profiling of cardiovascular disease and cardiovascular inflammation
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
US8114615B2 (en) 2006-05-17 2012-02-14 Cernostics, Inc. Method for automated tissue analysis
US20100009352A1 (en) * 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
EP2023874A4 (en) 2006-06-02 2009-07-08 Bioseek Inc METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
US20100112602A1 (en) * 2006-11-10 2010-05-06 Taylor Lansing D Protein-Protein Interaction Biosensors and Methods of Use Thereof
US20100093613A1 (en) * 2007-03-09 2010-04-15 Kunkel Eric J Methods for identifying agents and their use for the prevention or stabilization of fibrosis
WO2008121896A2 (en) 2007-03-30 2008-10-09 Bioseek, Inc. Methods for classification of toxic agents and counteragents
US8536135B2 (en) * 2008-03-19 2013-09-17 Ontherix, Inc. Adaptive biochemical signatures
CA2718969A1 (en) * 2008-03-19 2009-09-24 Ontherix, Inc. Adaptive biochemical signatures
ES2739623T3 (es) 2011-03-17 2020-02-03 Cernostics Inc Sistemas y composiciones para diagnosticar el esófago de Barrett y métodos para usarlos
US20170363614A1 (en) * 2014-12-22 2017-12-21 Enumeral Biomedical Holdings, Inc. Methods For Screening Therapeutic Compounds
WO2016168565A1 (en) * 2015-04-16 2016-10-20 President And Fellows Of Harvard College Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring
CN112466403B (zh) * 2020-12-31 2022-06-14 广州基迪奥生物科技有限公司 一种细胞通讯分析方法及系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067103A1 (en) * 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6763307B2 (en) * 2000-03-06 2004-07-13 Bioseek, Inc. Patient classification
US7266458B2 (en) * 2000-03-06 2007-09-04 Bioseek, Inc. BioMAP analysis
AU2002365904A1 (en) * 2001-07-10 2003-09-04 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
US7623969B2 (en) * 2002-01-31 2009-11-24 The Institute For Systems Biology Gene discovery for the system assignment of gene function
WO2003068054A2 (en) * 2002-02-13 2003-08-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Identification of ovarian cancer tumor markers and therapeutic targets
EP1620722A4 (en) * 2003-04-23 2008-01-30 Bioseek Inc METHODS FOR CHARACTERIZING SIGNALING PATHWAYS AND COMPOUNDS INTERACTING THEREWITH
WO2004094992A2 (en) * 2003-04-23 2004-11-04 Bioseek, Inc. Methods for analysis of biological dataset profiles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001067103A1 (en) * 2000-03-06 2001-09-13 Bioseek, Inc. Function homology screening

Also Published As

Publication number Publication date
EP1668361A2 (en) 2006-06-14
CA2576406A1 (en) 2005-03-17
WO2005023987A3 (en) 2005-12-08
EP1668361A4 (en) 2008-01-23
AU2004271183A1 (en) 2005-03-17
WO2005023987A2 (en) 2005-03-17
US20070072246A1 (en) 2007-03-29

Similar Documents

Publication Publication Date Title
US8467970B2 (en) Function homology screening
US20070072246A1 (en) Cell-based assays for determining drug action
Junkin et al. High-content quantification of single-cell immune dynamics
EP1436617B1 (en) Patient classification
Irish et al. Single cell profiling of potentiated phospho-protein networks in cancer cells
AU2001240074A2 (en) Function homology screening
AU2001240074A1 (en) Function homology screening
Papadopoulos et al. Assessment of interleukins IL-4, IL-6, IL-8, IL-10 in acute urticaria
US20070087344A1 (en) Methods for characterizing signaling pathways and compounds that interact therewith
US20070135997A1 (en) Methods for analysis of biological dataset profiles
Wang et al. Association of the psoriatic microenvironment with treatment response
Al Shahrani et al. High-throughput screening and in vitro evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-talk
JP2007527239A (ja) 喘息およびアトピーの生物学的データセットプロファイリング方法
von Boehmer T-cell development:: What does Notch do for T cells?
Lynall et al. Peripheral blood cell immunophenotyping reveals distinct subgroups of inflamed depression
Gerelkhuu et al. Immune Landscape Changes in MASLD and the Effects of 11β‐HSD1 Inhibition Revealed by Single‐Cell Mass Cytometry
Cakirca et al. Evaluation of Gas6 and sAxl levels during attacks and attack-free periods of familial Mediterranean fever
AU2002341654A1 (en) Patient classification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101027